Belzutifan: Belzutifan is administered orally at 120 mg once daily (qd) OR 200 mg qd until progressive disease (PD), unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
Nivolumab: Nivolumab is administered intravenously at 480 mg until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
Lenvatinib: Lenvatinib is administered orally at 20 mg qd until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
Cabozantinib: Cabozantinib is administered orally at 60 mg qd until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors:
* Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery
* Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids
* VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer
Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
| Facility | City | Region | Status |
|---|---|---|---|
| Beth Israel Deaconess Medical Center ( Site 0107) | Boston | Massachusetts | Recruiting |
| Dana-Farber Cancer Institute ( Site 0105) | Boston | Massachusetts | Recruiting |
| Karmanos Cancer Center ( Site 0108) | Detroit | Michigan | Recruiting |
| Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100) | Philadelphia | Pennsylvania | Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville | Tennessee | Recruiting |
| START San Antonio ( Site 0104) | San Antonio | Texas | Recruiting |
| Fred Hutchinson Cancer Center ( Site 0106) | Seattle | Washington | Recruiting |
| St George Hospital-Oncology Clinical Research Unit ( Site 2701) | Kogarah | New South Wales | Recruiting |
| Westmead Hospital ( Site 2703) | Sydney | New South Wales | Recruiting |
| Frankston Hospital-Oncology and Haematology ( Site 2705) | Frankston | Victoria | Recruiting |
| UZ Leuven ( Site 0900) | Leuven | Vlaams-Brabant | Recruiting |
| BP - A Beneficencia Portuguesa de São Paulo ( Site 0200) | São Paulo | São Paulo | Active Not Recruiting |
| Jewish General Hospital ( Site 0001) | Montreal | Quebec | Active Not Recruiting |
| James Lind Centro de Investigacion del Cancer ( Site 0304) | Temuco | Araucania | Recruiting |
| CIDO SpA ( Site 0305) | Temuco | Araucania | Recruiting |
| FALP ( Site 0300) | Santiago | Region M. de Santiago | Recruiting |
| Oncovida ( Site 0303) | Santiago | Region M. de Santiago | Recruiting |
| Bradfordhill ( Site 0301) | Santiago | Region M. de Santiago | Recruiting |
| ONCOCENTRO APYS ( Site 0302) | Viña del Mar | Valparaiso | Recruiting |
| Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1000) | Olomouc | Czechia | Recruiting |
| Herlev and Gentofte Hospital ( Site 1200) | Herlev | Capital Region | Recruiting |
| Tampereen yliopistollinen sairaala ( Site 1305) | Tampere | Pirkanmaa | Recruiting |
| Hôpitaux Universitaires de Strasbourg ( Site 1702) | Strasbourg | Bas-Rhin | Recruiting |
| Institut Claudius Regaud ( Site 1703) | Toulouse | Haute-Garonne | Recruiting |
| Gustave Roussy ( Site 1701) | Villejuif | Val-de-Marne | Recruiting |
| Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1501) | Budapest | Hungary | Recruiting |
| Rambam Health Care Campus ( Site 1600) | Haifa | Israel | Recruiting |
| Hadassah Medical Center ( Site 1604) | Jerusalem | Israel | Recruiting |
| Rabin Medical Center ( Site 1602) | Petah Tikva | Israel | Recruiting |
| Sheba Medical center ( Site 1601) | Ramat Gan | Israel | Recruiting |
| Sourasky Medical Center ( Site 1603) | Tel Aviv | Israel | Recruiting |
| Toranomon Hospital ( Site 3100) | Minato | Tokyo | Recruiting |
| Kyushu University Hospital ( Site 3101) | Fukuoka | Japan | Recruiting |
| Tokushima University Hospital ( Site 3102) | Tokushima | Japan | Recruiting |
| Maastricht Universitair Medisch Centrum - MUMC ( Site 1900) | Maastricht | Limburg | Recruiting |
| Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1901) | Amsterdam | North Holland | Recruiting |
| Isala, locatie Zwolle ( Site 1902) | Zwolle | Overijssel | Recruiting |
| Auckland City Hospital ( Site 3000) | Auckland | New Zealand | Recruiting |
| Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2000) | Bydgoszcz | Kuyavian-Pomeranian Voivodeship | Recruiting |
| N.N. Blokhin NMRCO ( Site 2101) | Moscow | Moscow | Active Not Recruiting |
+ 14 more sites — see the full list on the official registry below.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07405164 on ClinicalTrials.gov ↗ ← All trials in the Netherlands